Disseminated Intravascular Coagulation
- 1 January 1999
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 82 (08) , 695-705
- https://doi.org/10.1055/s-0037-1615899
Abstract
A quick literature search in the MEDLINE databases from 1966 to 1998 using the search term disseminated intravascular coagulation (DIC) and related key words yields an impressive 11,921 manuscripts. Most of the published literature concerns the pathophysiology of DIC, which in its main features is now well understood. Other aspects of DIC, however, particularly those related to the definition, the relevance of the syndrome, and clinical management, remain unclear. Taking an evidence-based approach to the appropriate diagnosis and treatment of patients with DIC is difficult, in view of the lack of sound clinical trials. This is probably due to the fact that DIC is a poorly-defined syndrome with a widely variable intensity, often complicating a diversity of severe disorders that are themselves related to extensive morbidity and mortality.1,2 This chapter briefly reviews the clinical setting, incidence, and relevance of DIC and current insights into the pathogenesis of DIC. It also discusses the available knowledge on the clinical management of patients with this syndrome. DIC is not a disease or a symptom but rather a syndrome, which is always secondary to an underlying disorder. The syndrome is characterized by a systemic activation of the blood coagulation system, which results in the generation and deposition of fibrin, leading to microvascular thrombi in various organs and contributing to the development of multiorgan failure. Consumption and subsequent exhaustion of coagulation proteins and platelets, due to the ongoing activation of the coagulation system, may induce severe bleeding complications, although microclot formation may occur in the absence of severe clotting factor depletion and bleeding.3 Derangement of the fibrinolytic system further contributes to intravascular clot formation (discussed later), but in some cases accelerated fibrinolysis (e.g., due to consumption of α2-antiplasmin) may cause severe bleeding. Hence, a patient with DIC can present with simultaneous thrombotic and bleeding problems, which obviously complicates treatment. Although there is no general consensus regarding the definition of DIC, the definition as put forward by Müller-Berghaus and colleagues in 1995 might be most appropriate: “Disseminated intravascular coagulation is an acquired syndrome characterized by the activation of intravascular coagulation up to intravascular fibrin formation. The process may be accompanied by secondary fibrinolysis or inhibited fibrinolysis.”4Keywords
This publication has 32 references indexed in Scilit:
- Procoagulant activity in patients with isolated severe head traumaCritical Care Medicine, 1998
- Fortnightly Review: Disseminated intravascular coagulation: diagnosis and treatmentBMJ, 1996
- DIC Pathogenesis Diagnosis and Therapy of Disseminated Intravascular Fibrin FormationBlood Coagulation & Fibrinolysis, 1995
- Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice.Journal of Clinical Investigation, 1994
- Elevated plasma tissue factor antigen level in patients with disseminated intravascular coagulationAmerican Journal of Hematology, 1994
- Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.Journal of Clinical Investigation, 1993
- The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons.Journal of Clinical Investigation, 1993
- Activation of Coagulation after Administration of Tumor Necrosis Factor to Normal SubjectsNew England Journal of Medicine, 1990
- Acquired antithrombin III deficiency: Laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrateThe American Journal of Medicine, 1989
- Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells.Molecular and Cellular Biology, 1988